Research programme: next generation neuroprotectants - Renovis

Drug Profile

Research programme: next generation neuroprotectants - Renovis

Latest Information Update: 01 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Renovis
  • Class
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS trauma; Stroke

Most Recent Events

  • 07 Jun 2005 This programme is still in active development
  • 26 May 2004 Preclinical trials in CNS trauma in USA (PO)
  • 26 May 2004 Preclinical trials in Stroke in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top